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Abstract
Background: Inflammation plays a key role in atherosclerosis. Sirt1 regulates transcription factors involved in inflammatory
processes and blunts atherosclerosis in mice. However, its role in humans remains to be defined. This study was therefore
designed to investigate the role of Sirt1 in the development of atherosclerosis.
Methods and Results: 48 male subjects admitted for cardiac catheterization were subdivided into healthy subjects, patients
with stable coronary artery disease (CAD), and with acute coronary syndromes (ACS). Monocytes were isolated and Sirt1
mRNA levels were determined. Sirt1 gene expression was higher in healthy subjects as compared to patients with CAD or
ACS (P,0.05), respectively. Interestingly, HDL levels correlated positively with Sirt1 expression. Thus, HDL from the three
groups was isolated and incubated with THP-1 monocytes to determine the effects of HDL on Sirt1 protein in controlled
experimental conditions. HDL from healthy subjects stimulated Sirt1 expression in THP-1 monocytes to a higher degree
than HDL from CAD and ACS patients (P,0.05). Paraoxonase-1 (PON-1), a HDL-associated enzyme, showed a reduced
activity in HDL isolated from CAD and ACS patients as compared to the controls (P,0.001).
Conclusions: Monocytic Sirt1 expression is reduced in patients with stable CAD and ACS. Experiments on THP-1 monocytes
suggest that this effect is HDL-dependent and is mediated by a reduced activity of HDL-associated enzyme PON1.
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Introduction
Coronary artery disease (CAD) represents a major health
burden and accounts for the majority of deaths in the Western
civilisation. CAD is associated with atherosclerotic plaques, while
endothelial erosion and plaque rupture with a superimposed
thrombus is the underlying pathophysiological process leading to
acute coronary syndromes (ACS) [1]. There is growing evidence
that both development of atherosclerotic lesions as well as
atherothrombotic complications are driven by inflammatory
processes initiated by modified lipoproteins and other risk factors
[2]. Circulating monocytes are thereby critically involved since
monocyte infiltration into the arterial vessel wall represents the
initial step of atherosclerotic plaque formation [3].
The mammalian silent information regulator-two 1 (Sirt1) is a
NAD+-dependent class III histone deacetylase [4]. In addition to
maintaining chromatin structure, Sirt1 regulates the activity of
various transcription factors which act as key players in
inflammatory processes [5]. In line with this, there is growing
evidence that Sirt1 is critically involved in CAD. Indeed, in a
mouse model of atherosclerosis, partial deletion of Sirt1 in bone
marrow-derived macrophages promotes the development of
atherosclerotic plaques [6].
Based on the above, the question arises whether Sirt1 expression
in monocytes of patients suffering from CAD or ACS is altered as
compared to subjects without coronary artery disease.
Methods
Patient Data
Male subjects aged 48–65 years admitted to the cardiac
catheterization unit at the University Hospital Zurich between
December 2009 and September 2011 for coronary angiography
were included in the study. Patients suffering from diabetes
mellitus, as well as individuals diagnosed with an active neoplastic,
infectious of autoimmune disease were not included in the study
population. For the CAD group, a history of ACS ,6 months
prior to the study was considered as an exclusion criterion.
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Ethics Statement
Ethical approval was granted by the institutional ethical
committee (Kantonale Ethikkommission Zu¨rich). All subjects
signed an informed consent form.
Data Acquisition Procedures
Coronary atherosclerosis was determined by quantitative
coronary angiography. Criteria for study group assignment were
(a) no angiographically identifiable coronary stenosis (.20%) or
diffuse coronary atherosclerosis for the control group, (b) at least
one stenosis $75% in either left, circumflex or right coronary
artery for the CAD group and (c) either a ST-elevation (typical
chest pain and two ST segment elevations$0.1 mV) or a non-ST-
elevation (typical chest pain with four-fold elevation of Troponin
T) myocardial infarction, both being admitted for percutaneous
coronary intervention, for the ACS group. Previous medication
was not discontinued for this study. Blood pressure was measured
in horizontal position using automatic blood pressure meters, and
body weight as well as height were measured on hospital
admission. Smoking was defined as cigarette consumption of
.10 cigarettes/day. Blood parameters were measured on auto-
mated routine analyzers.
Isolation of Peripheral Blood Monocytes
Blood was collected in Ficoll tubes (Vacutainer CPT, BD
Diagnostics) and centrifuged for 20 min at 1800 g and room
temperature. The turbid white layer above the Ficoll containing
Figure 1. Sirt1 expression is reduced in patients suffering from atherosclerotic disease. A. HDL levels are reduced in patients suffering
from CAD or ACS as compared to the healthy controls. B. Flow cytometry analysis demonstrates the purity of isolated monocytes. C. Sirt1 mRNA
expression in relation to 18S rRNA in peripheral blood monocytes isolated from healthy subjects, from patients with angiographically-confirmed CAD
and patients presenting with an ACS. D. The expression of interleukin-6 (IL-6), a negatively regulated Sirt1-dependent marker, is increased in patients
with impaired Sirt1-expression.
doi:10.1371/journal.pone.0053106.g001
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the mononuclear blood cells was transferred to a clean tube and
washed twice with PBS. Subsequently, monocytes were isolated
using magnetic CD14-coated beads and magnetic activated cell
sorting (MACS). Purity of isolated monocytes was tested by flow
cytometry in cells stained with a fluorescin-labeled CD14-
antibody. Finally, isolated cells were resuspended in TRIzol
reagent (Invitrogen) and the total RNA extract was stored at
280uC.
Measurement of Sirt1 mRNA Levels by Real-time PCR
Total RNA was extracted from PBM with 1 mL TRIzol
Reagent (Invitrogen) as described [7]. Conversion of total cellular
RNA to cDNA was carried out with Moloney murine leukemia
virus reverse transcriptase and random hexamer primers (Amer-
sham) in a final volume of 33 mL using 4 mg of RNA. The total
cDNA pool obtained served as template for subsequent PCR
amplification with primers specific for human Sirt1 (Forward
primer sequence 59-TGAGGCACTTCATGGGGTATGG-39,
reverse primer sequence 59-TCCTAGGtTGCCCAGCTGAT-
GAA-39). Real-time PCR amplification was performed in an
MX3000P PCR cycler (Stratagene) using the SYBR Green
JumpStart kit (Sigma) in 25 mL final reaction volume containing
2 mL cDNA, 10 pmol of each primer, 0.25 mL of internal
reference dye, and 12.5 mL of JumpStart Taq ReadyMix (buffer,
dNTP, stabilizers, SYBR Green, Taq polymerase, and JumpStart
Taq antibody). The amplification program consisted of 1 cycle at
95uC for 10 minutes, followed by 40 cycles at 95uC for 30 seconds,
57uC for 1 minute and 72uC for 1 minute. A melting curve
analysis was performed after amplification to verify the accuracy of
the amplicon. Ribosomal S12 RNA served as loading control.
Measurement of Serum Interleukin-6 (IL-6)
IL-6 protein expression was determined using chemilumines-
cence immunoassays from DPC (Bu¨hlmann), on an Immulite 2000
analyzer with a maximal variation coefficient of 11%. 50 ml of
plasma from each patient was used.
HDL Isolation
HDL from the three patient groups was isolated by sequential
ultracentrifugation (d=1.063–1.21 g/mL) using solid potassium
bromide (Merck) for density adjustment as described previously
[8,9]. Blood samples were processed within 1 hour after collection.
Cell Culture Experiments
THP-1 cells (LGC Promochem) were cultured as described
previously [10]. Briefly, cells were grown to confluence (26106
cells per mL) in 3 cm cell culture dishes with RPMI 1640
containing 10% fetal calf serum (FCS) and rendered quiescent for
24 hours in medium with reduced amount of FCS (0.5%) before
pretreatment with isolated HDL (10 mg/mL). HDL was added 6
hours before cell lysis.
Western Blotting
Cells were lysed in a buffer solution (50 mM Tris pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM NaF, 0.1 mM Na3VO4,
0.5% NP-40, 10 mg/mL Aprotinin, 10 mg/mL Leupeptin, 1 mM
PMSF, and 1 mM DTT). 25 mg protein were loaded per lane, and
10% SDS-PAGE was performed. Proteins were transferred to
PVDF membranes (Millipore) by semidry transfer. An antibody
against human Sirt1 (Santa Cruz) was used at 1:29000 dilution. An
Table 1. Clinical characteristics of the three patient groups.
Control (n =13) CAD (n=19) ACS (n=16) P value
Gender [m/f] 13/0 19/0 16/0 NS
Age [years] 5963.8 59.863.8 58.764.3 NS
Systolic BD [mmHg] 13269 135614 135621 NS
Diastolic BD [mmHg] 79610 7867 84616 NS
BMI [kg/m2] 27.164.2 28.064.2 27.665.1 NS
Total cholesterol [mmol/L] 4.661.2 4.360.7 5.361.1 ,0.05*
LDL cholesterol [mmol/L] 2.661.2 2.560.6 3.560.9 ,0.05*
HDL cholesterol [mmol/L] 1.460.4 1.160.2 1.160.2 ,0.05{,{
CRP [mg/L] 1.461.0 2.463.2 8.469.3 ,0.05*
Adipositas 3 (23.1) 5 (26.3) 4 (25.0) NS
Dyslipidemia 4 (30.8) 10 (52.6) 9 (52.9) ,0.05{,{
Hypertension 5 (38.5) 11 (57.9) 11 (64.7) ,0.05{,{
Current smoking 3 (23.1) 3 (15.8) 7 (41.2) ,0.05*
Aspirin 6 (46.2) 14 (73.7) 14 (73.7) ,0.05{,{
Clopidogrel 0 (0) 7 (36.8) 7 (36.8) ,0.05{,{
Beta-Blocker 4 (30.8) 9 (47.4) 9 (47.4) NS
ACEI/ATB 6 (46.2) 9 (47.4) 9 (47.4) NS
Statins 5 (38.5) 13 (68.4) 13 (68.4) ,0.05{,{
Diuretics 2 (15.4) 3 (15.8) 3 (15.8) NS
*0.05* CADnts with CAD and ACS,ACS group)erosclerosis looses its cardioprotectice properties.**
*ACS vs CAD.
{Healthy vs CAD.
{Healthy vs ACS.
doi:10.1371/journal.pone.0053106.t001
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antibody against glycerinaldehyd-3-phosphat-dehydrogenase
(GAPDH, 1:209000, Sigma) was applied as loading control.
Measurement of PON1 Activity
Arylesterase activity of HDL-associated paraoxonase was
measured by spectrophotometry using the substrate phenylacetate.
Statistical Analysis
Continuous variables are expressed as median (interquartile
range) and frequencies for categorical variables. The inclusion of
14 patients in each group, for a P-value of 0.05 (two-tailed;
assuming a difference in densitometric unit of 0.1 and a standard
deviation of 0.08), has the power to detect a significant difference
of 91%. Clinical data was analyzed by the x2 test for categorical
and by the Mann-Whitney-U test for continuous data. Spearman’s
correlation analysis was used to assess correlation between
variables. For Western Blotting, ELISA, and real-time PCR
nonparametric one-way ANOVA with Bonferroni post-hoc
analysis was performed. The level of significance was defined as
a two-tailed P value ,0.05. All statistical analyses were performed
with SPSS Statistics 19.0 for Windows (SPSS, Inc. 2010).
Results
Patient’s Characteristics
48 subjects were included in the present study (13 age-matched,
control subjects without coronary artery disease, 19 CAD and 16
ACS patients, respectively). A detailed overview of the patient’s
characteristics is summarized in table 1. Briefly, medium age was
59 years and all patients were of Caucasian origin. In the CAD
group, 4 subjects (21%) had one, 4 (21%) had two and 11 (58%)
had three vessel disease. In the ACS group, 7 patients suffered
from ST-segment elevation myocardial infarction (STEMI; 39%)
and 11 of Non-ST-segment elevation myocardial infarction
(NSTEMI; 61%). Myocardial infarction has been diagnosed based
on findings on electrocardiography and laboratory markers of
myocardial necrosis, i.e. troponin T and creatine kinase.
Importantly, CRP levels were higher in patients with ACS
(P,0.05 vs healthy and CAD). As expected, more patients in
the CAD group took anti-platelet drugs and statins as compared to
healthy people as well as the ACS group (P,0.05 for CAD vs
healthy and ACS group). Interestingly, higher HDL cholesterol
levels were found in the healthy group as compared to CAD and
ACS patients (P,0.05 for healthy vs CAD and ACS group;
Figure 1A).
Sirt1 Expression is Decreased in Patients with Coronary
Artery Disease
Flow cytometry analysis of the isolated monocytes stained for
CD14 demonstrated the high degree of purity of the isolated cells
(Figure 1B). Sirt1 mRNA levels in monocytes were significantly
higher in healthy controls (0.079160.019; n = 13; Figure 1C) as
compared to CAD (0.04160.004; n= 19; P,0.05 vs control) and
ACS patients (0.04260.005; n= 18; P,0.05 vs control). However,
expression levels of Sirt1 did not differ significantly between CAD
and ACS patients (P=NS).
To confirm Sirt1 pathway inhibition in CAD and ACS patients,
expression of Sirt1-negatively regulated downstream target inter-
leukin-6 (IL-6) [11] was determined. In line with our expectation,
IL-6 protein expression was upregulated in the same patient
groups (n = 10–12; P,0.05; Figure 1D).
HDL from Healthy Patients Increases Monocyte Sirt1
Expression, while HDL from CAD and ACS Patients does
not
In order to assess potential direct effects of HDL on Sirt1, THP-
1 cells, a monocyte cell line, were incubated with HDL isolated
from healthy subjects, CAD or ACS patients, respectively, and
Sirt1 protein expression analyzed by Western blotting. As shown
in figure 2A, HDL from healthy subjects increased Sirt1 protein
expression as compared to vehicle-treated cells (n = 5–11, P,0.05
vs control; Figure 2A), while HDL from to CAD and ACS did not
(n = 9–12; P=NS vs control, Figure 2A).
Figure 2. HDL regulates Sirt1 expression. A. Sirt1 protein
expression in THP1 cells after incubation with HDL from healthy
subjects or patients suffering from CAD and ACS, respectively. B. PON1
function, as measured by PON1 arylesterase activity, is significantly
reduced in the CAD and ACS group.
doi:10.1371/journal.pone.0053106.g002
Sirt1 and Atherosclerosis
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Paraoxonase 1 (PON1) Activity is Reduced in CAD and
ACS Patients
PON1 is a HDL-associated enzyme which has been demon-
strated to affect atherosclerosis [12]. Therefore, PON1 activity was
measured in HDL from healthy subjects, CAD and ACS patients.
As shown in Figure 2B, PON1 activity is significantly reduced in
the CAD and ACS group as compared to the healthy control
(n = 9; P,0.001; Figure 2B).
Discussion
Here we demonstrate for the first time that the expression levels
of the longevity gene Sirt1 in peripheral blood monocytes is
reduced in patients with stable CAD and in those with ACS,
respectively, as compared to subjects without angiographically
demonstrable CAD. Interestingly, Sirt1 levels correlated positively
to HDL levels in all three study groups. In line with this
observation, THP-1 monocytic cells incubated with HDL isolated
from healthy subjects displayed increased Sirt1 protein expression
as compared to THP-1 monocytic cells incubated with HDL from
the CAD or ACS group. Furthermore, PON1 activity was reduced
in HDL from CAD and ACS groups as compared to healthy
subjects, indicating that PON1 activity is required in order for
HDL to stimulate Sirt1 expression.
Sirt1, a key regulator of inflammatory processes, reduces
atherosclerosis in different animal models [6,13]. Importantly,
Sirt1 in endothelial cells and Sirt1 from bone marrow-derived
macrophages are both involved in this anti-atherogenic effect.
However, whether Sirt1 also displays anti-atherogenic properties
in humans and in CAD patients in particular, has not yet been
shown. In the present study, we report that monocyte Sirt1 gene
expression is decreased in patients suffering from coronary
atherosclerosis; in line with this, expression of Sirt1-negatively
regulated downstream target interleukin-6 (IL-6) [11] was
increased in the same patient groups. Although, as shown
previously, CRP was elevated in ACS patients compared to stable
CAD, acute activation of the immune system – at least as reflected
by an elevated C-reactive protein in the ACS group – does not
seem to play a role in the regulation of Sirt1 expression. This
finding is in line with results from in vitro studies, were acute
stimulation of cultured endothelial cells with inflammatory
cytokines did not change Sirt1 protein expression [5]. However,
whether the impaired Sirt1 levels in patients suffering from
coronary atherosclerosis are a result of the atherosclerotic process
itself or vice versa, cannot be answered by this study.
Interestingly, Sirt1 expression correlated positively with the
plasma levels of HDL cholesterol suggesting a regulatory role of
HDL on Sirt1 expression. Indeed, epidemiologically HDL plasma
levels are inversely related to myocardial infarction and stroke
even in patients treated with a statin [14]. In contrast to the well-
known pro-atherogenic LDL cholesterol [15,16], HDL can exert
profound vascular protective functions [17]. Of note, recently
published data from our institution examining the endothelial
protective role of HDL showed that its beneficial properties are
lost in specific subset of patients indicating that HDL plasma levels
may not reflect the functional properties of the lipoprotein [9,18].
Indeed, HDL from CAD and ACS patients, unlike that of healthy
subjects, fails to stimulate endothelial nitric oxide production in
human aortic endothelial cells, underscoring a loss of its anti-
atherogenic properties [9]. Our in vitro data are in line with these
recent findings, since HDL from healthy subjects increased Sirt1
protein expression in THP-1 cells, while matching concentrations
of HDL from CAD and ACS patients failed to do so. Thus, in this
setting, not only the reduced plasma levels of HDL in patients with
CAD and ACS must have contributed to the reduced Sirt1
expression, but – since these data have been obtained with
matching HDL concentrations in all three experimental groups –
also a biological dysfunction of the HDL particles associated with
CAD and ACS.
PON1 is a HDL-associated antioxidant enzyme that has been
shown to reduce the development of atherosclerotic lesions in mice
[19], while low activity of PON1 in humans is associated with the
risk of CAD and cardiovascular events [12]. Interestingly, PON1
activity was reduced in HDL isolated from CAD and ACS patients
in our study. Loss of PON1 activity results in a reduced level of
endothelial nitric oxide synthase (eNOS) activity [9], which is an
upstream target of Sirt1. Hence, normal PON1 activity appears
essential for Sirt1 expression.
In summary, we here demonstrate for the first time that in
patients with CAD and ACS monocyte Sirt1 expression levels are
markedly decreased as compared to healthy individuals. While
treatment of a human monocyte cell line with HDL isolated from
healthy people raised Sirt1 expression, HDL obtained from
patients with CAD and ACS completely failed to do so, probably
due to the loss of PON1 activity. The reduced Sirt1 levels in CAD
and ACS therefore appear to be related both to reduced HDL
levels and HDL dysfunction.
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